iTeos Therapeutics Initiates Phase 1/2 Study with Highly Innovative Anti-TIGIT Antibody in Patients with Advanced Cancers

iTeos Therapeutics Initiates Phase 1/2 Study with Highly Innovative Anti-TIGIT Antibody in Patients with Advanced Cancers

Clinical Trials Research TIGIT
– First patient enrolled in dose escalation portion of Phase 1/2 study of EOS-448, an antagonist anti-TIGIT antibody that enables antibody dependent cellular cytotoxicity (ADCC) – – ADCC-enabled TIGIT programs are progressing into pivotal trials – – Initial clinical data expected in 1H…
Read more

Previous news

  • iTeos Therapeutics Initiates Phase 1/1b Trial with Differentiated Adenosine A2A Antagonist in Patients with Advanced Cancer
    Clinical Trials

    iTeos Therapeutics Initiates Phase 1/1b Trial with Differentiated Adenosine A2A Antagonist in Patients with Advanced Cancer

    First cohort of patients with advanced cancer now dosed with EOS100850 - Target enrollment of 72 patients; initial clinical data expected in Q4 2019 Gosselies, Belgium and Cambridge, MA – April 17, 2019 – iTeos Therapeutics SA, a privately-held biotechnology company developing novel cancer immunotherapies, announced today the first cohort of patients has been dosed in its Phase 1/1b study with EOS100850, the Company’s investigational A2Areceptor antagonist and lead program candidate. “I am tremendously excited to announce that patient dosing in our innovative, adaptive Phase 1/1b trial is now underway with EOS100850, our unique and specific A2Areceptor antagonist. We believe we have a potential best-in-class compound, which was carefully designed with differentiating features to maximize the therapeutic window,” said Michel Detheux, Ph.D., Co-Founder, President and Chief Executive Officer of iTeos. “The A2A pathway has emerged as one of the most exciting targets due to the emerging clinical evidence validating the important role adenosine plays in suppressing the immune response to cancer in the tumor microenvironment. EOS100850 addresses the therapeutic challenges found within this tumor microenvironment by achieving a higher degree of receptor inhibition with its PK/PD and non-brain penetrant profile and its ability to maintain potent efficacy despite increased levels of adenosine concentrations. We are optimistic that EOS100850 can restore the immune response and may control cancer for patients in multiple indications.”  About the EOS100850 Phase 1/1b Trial This state-of-the-art Phase 1/1b study of EOS100850 will include an extended translational medicine strategy with pre- and post-biopsies, which will enable researchers to identify and confirm relevant biomarkers to be used in further clinical development. Key objectives in this flexible, open-label, dose-escalation study include understanding the safety and tolerability of the compound and determining a recommended Phase 2 dose. The pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity will also be evaluated. The trial will be conducted at multiple clinical sites in Belgium, the United Kingdom and the United States and is expected to enroll 72 patients with advanced cancer. The dose escalation and dose expansion cohorts will include a comprehensive effort to evaluate the activity in specific tumor types as well as to confirm the advantageous PK/PD profile of EOS100850. Disease-specific expansion cohorts will be enrolled at the optimal Phase 2 dose.  For more information on this trial, please visit www.clinicaltrials.gov (Identifier: NCT03873883). About the iTeos Adenosine A2A Receptor Antagonist (EOS100850) The high level of adenosine in the microenvironment of many tumors plays a significant role in tumor immune evasion. The adenosine A2A receptor is the primary adenosine receptor expressed on immune cells. In the presence of adenosine, this receptor suppresses T cell activity. In preclinical studies, EOS100850, iTeos’ A2A receptor antagonist, restores T cell activity and promotes anti-tumor activity in preclinical models, as well as synergizing with several immune-checkpoint inhibitors and chemotherapy. Preliminary evidence of clinical activity has been described in kidney, lung and prostate cancer in clinical studies of A2A receptor antagonists and other agents targeting the adenosine axis. In contrast to other clinical-stage A2A receptor antagonists, EOS100850 retains high potency in the presence of elevated adenosine concentrations measured in the tumor microenvironment and is non-brain penetrant. EOS100850 has been extensively evaluated for safety, efficacy and oral bioavailability in numerous preclinical models. About iTeos Therapeutics  iTeos Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to transforming the lives of persons living with cancer by designing and developing next generation immunotherapies. The Company’s lead program, EOS100850, is an adenosine A2A receptor antagonist currently in a Phase 1/1b study. A second program, a fully human ADCC-enabling anti-TIGIT antibody (EOS884448), is expected to enter the clinic in the second half of 2019. Based in Gosselies, Belgium and Cambridge, MA, iTeos Therapeutics was founded through the Ludwig Institute for Cancer Research (LICR) and the de Duve Institute (Université Catholique de Louvain). In 2018, the Company completed a $75 million (€64 million) Series B financing led by MPM Capital, along with new investors HBM Partners, 6 Dimensions Capital and Curative Ventures. Previous investors, including Fund +, VIVES II and SRIW, as well as SFPI, also participated in this funding round. For more information, please visit www.iteostherapeutics.com.   For further information, please contact: Michel Detheux, CEO iTeos Therapeutics SA info@iteostherapeutics.com   Amber Fennell, Mathew Neal and Sukaina Virji Consilium Strategic Communications +44 203 709 5700 iteos@consilium-comms.com   Sarah McCabe and Carl Mauch Stern Investor Relations, Inc. + 1 212 362 1200 iteos@sternir.com

  • iTeos Therapeutics Announces Eight Data Presentations for A2A Receptor Antagonist and Anti-TIGIT Antibody Programs at AACR Annual Meeting 2019
    A2A Inhibitor TIGIT

    iTeos Therapeutics Announces Eight Data Presentations for A2A Receptor Antagonist and Anti-TIGIT Antibody Programs at AACR Annual Meeting 2019

    Gosselies, Belgium and Cambridge, MA – March 29, 2019 – iTeos Therapeutics SA, a privately-held biotechnology company developing novel cancer immunotherapies, today announced that it will present data on the efficacy of its innovative and differentiated A2A receptor antagonist, EOS100850, as well as its human antibody directed against TIGIT, EOS884448, in eight posters at the upcoming American Association of Cancer Research (AACR) Annual Meeting 2019, taking place from March 29 - April 3, 2019 in Atlanta, Georgia.  “We continue to be excited by the preclinical data from our two immuno-oncology programs, both of which promise mono- and combination therapy potential with other anti-cancer treaments,” said Michel Detheux, President and Chief Executive Officer of iTeos Therapeutics. “The preclinical data being presented at AACR demonstrate key differentiation of our A2A receptor antagonist, such as unique prolonged effects of high potency within the adenosine-rich tumor microenvironment and anti-tumor activity in several cancer models and with different drug combinations. The data also provide a deeper understanding of the adenosine pathway in solid tumors. Additionally, our research on the TIGIT activation pathway sheds light on promising strategies to restore anti-tumor immunity.”  The details of the poster presentations are as follows: Title: EOS100850, a non-brain penetrant highly selective A2A receptor antagonist, uniquely maintains high potency within the adenosine rich tumor microenvironment  Session: Novel Immunomodulatory Agents 1 Date & Time: Tuesday, April 2, 2019, 8:00 AM - 12:00 PM ET Authors: Erica Houthuys, et al. Location: Section 25, Poster 3261 Title: EOS100850 potently restores adenosine A2A receptor-dependent suppression of T cell function in the adenosine rich tumor microenvironment  Session: Novel Immunomodulatory Agents 1  Date & Time: Tuesday, April 2, 2019, 8:00 AM - 12:00 PM ET Authors: Erica Houthuys, et al. Location: Section 25, Poster 3278  Title: Extensive characterization of the adenosine pathway in human solid tumors gives a hint on cancer indication selection for the A2A receptor antagonist EOS100850. Session: Novel Immunomodulatory Agents 2 Date & Time: Tuesday, April 2, 2019, 1:00 PM - 5:00 PM ET Authors: Veronique Bodo, et al.  Location: Section 25, Poster 4149  Title: EOS100850 inhibits A2A receptor signaling in human whole blood: two pharmacodynamic assays to monitor EOS100850 activity in clinical studies. Session: Novel Immunomodulatory Agents 2 Date & Time: Tuesday, April 2, 2019, 1:00 PM - 5:00 PM ET Authors: Veronique Bodo, et al. Location: Section 25, Poster 4154 Title: EOS100850, an A2A receptor antagonist with prolonged pharmacodynamic activity, mediates the generation of specific durable immune responses in a murine breast cancer model  Session: Novel Immunomodulatory Agents 2 Date & Time: Tuesday, April 2, 2019, 1:00 PM - 5:00 PM ET Authors: Grégory Driessens, et al.  Location: Section 25, Poster 4147  Title: EOS884448, a high affinity fully human antibody directed against TIGIT, mediates in vitro anti-tumor activity through multiples mechanisms of action involving activation of intratumor effector cells and depletion of regulatory T cells. Session: Immune Checkpoints 1 Date & Time: Tuesday, April 2, 2019, 8:00 AM - 12:00 PM ET Authors: Catherine Hoofd, et al. Location: Section 24, Poster 3240 Title: a-TIGIT mediates antitumor activity through multiple mechanisms of action involving activation of intratumor effector T cells and depletion of regulatory T cells  Session: Immune Checkpoints 1 Date & Time: Tuesday, April 2, 2019, 8:00 AM - 12:00 PM ET  Authors: Grégory Driessens, et al. Location: Section 24, Poster 3249 Title: TIGIT pathway phenotyping sheds light on promising strategies to restore anti-tumor immunity Session: Adaptive Immune Cells in the Tumor Microenvironment Date & Time: Wednesday, April 3, 2019, 8:00 AM - 12:00 PM ET  Authors: Catherine Hoofd, et al. Location: Section 23, Poster 4969 Full poster abstracts are available on the AACR conference website at www.aacr.org.  About iTeos Therapeutics  iTeos Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to transforming the lives of persons living with cancer by designing and developing next generation immunotherapies. The Company’s lead program, EOS100850, is an adenosine A2A receptor antagonist currently in a Phase 1/1b study. A second program, a fully human ADCC-enabling anti-TIGIT antibody (EOS884448), is expected to enter the clinic in second half of 2019. Based in Gosselies, Belgium and Cambridge, MA, iTeos Therapeutics was founded through the Ludwig Institute for Cancer Research (LICR) and the de Duve Institute (Université Catholique de Louvain). In 2018, the Company completed a $75 million (€64 million) Series B financing led by MPM Capital, along with new investors HBM Partners, 6 Dimensions Capital and Curative Ventures. Previous investors, including Fund +, VIVES II and SRIW, as well as SFPI, also participated in this funding round. For more information, please visit www.iteostherapeutics.com. For further information, please contact: Michel Detheux, CEO iTeos Therapeutics info@iteostherapeutics.com  Amber Fennell, Mathew Neal, Sukaina Virji Consilium Strategic Communications +44 203 709 5700 iteos@consilium-comms.com Sarah McCabe and Carl Mauch Stern Investor Relations, Inc. + 1 212 362 1200 iTeos@sternir.com   

  • iTeos Therapeutics Appoints Joanne Jenkins Lager, M.D., as Chief Medical Officer
    Clinical Trials Corporate

    iTeos Therapeutics Appoints Joanne Jenkins Lager, M.D., as Chief Medical Officer

    Gosselies, Belgium and Cambridge, MA – March 26, 2019 – iTeos Therapeutics SA, a privately-held biotechnology company developing novel cancer immunotherapies, today announced the appointment of Joanne Jenkins Lager, M.D., as Chief Medical Officer of iTeos, effective April 1, 2019. “We are extremely pleased to welcome Dr. Lager as our Chief Medical Officer at such an exciting time at iTeos. With our Phase 1 program for our A2A receptor antagonist, EOS100850, underway and our second TIGIT antibody program entering the clinic later this year, we believe our strategic approach has the potential to overcome the significant challenges faced in the immuno-oncology field,” said Michel Detheux, Ph.D., President and Chief Executive Officer of iTeos. “We look forward to benefiting from Joanne’s substantial oncology experience and proven clinical development leadership as we continue to design and develop our next generation immunotherapies to improve the lives of cancer patients worldwide.” Dr. Lager joins iTeos from Sanofi, where she served as Vice President, Head of Global Oncology Development since 2014. In that capacity, she oversaw the development strategy and operations for the company’s early and late-stage clinical development portfolio including both hematologic and solid tumor malignancies. She also served as the co-lead of the Oncology Leadership Team, co-chair of the Therapeutic Area Review Committee and chair of the Oncology Protocol Review Committee. Prior to Sanofi, Dr. Lager served at GlaxoSmithKline in various levels of increasing responsibility, including as Clinical Head of the Cancer Metabolism Discovery Performance Unit. In that capacity, she oversaw the analysis of new targets and undertook early phase clinical studies of oncology drugs. Dr. Lager received her M.D. from Duke University School of Medicine and B.A. in Psychobiology from Wellesley College. “I am joining iTeos as CMO at a transformational stage in the company’s development,” said Joanne Jenkins Lager, M.D., incumbent Chief Medical Officer of iTeos Therapeutics. “I’m excited about the potential of the company’s best-in-class programs to improve treatment for cancer patients.” About iTeos Therapeutics iTeos Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to transforming the lives of persons living with cancer by designing and developing next generation immunotherapies. The Company’s lead program, EOS100850, is an adenosine A2A receptor antagonist currently in a Phase 1/1b study. A second program, a fully human ADCC-enabling anti-TIGIT antibody (EOS884448), is expected to enter the clinic in second half of 2019. Based in Gosselies, Belgium and Cambridge, MA, iTeos Therapeutics was founded through the Ludwig Institute for Cancer Research (LICR) and the de Duve Institute (Université Catholique de Louvain). In 2018, the Company completed a $75 million (€64 million) Series B financing led by MPM Capital, along with new investors HBM Partners, 6 Dimensions Capital and Curative Ventures. Previous investors, including Fund +, VIVES II and SRIW, as well as SFPI, also participated in this funding round. For more information, please visit www.iteostherapeutics.com. For further information, please contact: Michel Detheux, CEO iTeos Therapeutics info@iteostherapeutics.com Amber Fennell, Mathew Neal, Sukaina Virji Consilium Strategic Communications +44 203 709 5700 iteos@consilium-comms.com Sarah McCabe and Carl Mauch Stern Investor Relations, Inc. + 1 212 362 1200 iTeos@sternir.com

  • iTeos Therapeutics to Participate in Upcoming U.S. Conferences in March
    Corporate

    iTeos Therapeutics to Participate in Upcoming U.S. Conferences in March

    Gosselies, Belgium – March 5, 2019 – iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announced that Michel Detheux, Ph.D., Chief Executive Officer of iTeos, will present in two upcoming U.S. conferences in March.  Cowen & Company 39th Annual Health Care Conference on Tuesday, March 12, 2019 at 11:30 a.m. ET in Boston, MA. William Blair 9th Annual Cancer Immunotherapy Conference on Thursday, March 21, 2019 at 3:15 p.m. ET in New York, NY.   About iTeos Therapeutics iTeos Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to transforming the lives of persons living with cancer by designing and developing next generation immunotherapies. The Company’s lead program, EOS100850, is a best in class adenosine A2A receptor antagonist currently in a Phase 1/1b study. A second program, a fully human ADCC-enabling anti-TIGIT antibody (EOS884448), is expected to enter the clinic in second half of 2019. Based in Gosselies, Belgium and Cambridge, MA, iTeos Therapeutics was founded through the Ludwig Institute for Cancer Research (LICR) and the de Duve Institute (Université Catholique de Louvain). In 2018, the Company completed a $75 million (€64 million) Series B financing led by MPM Capital, along with new investors HBM Partners, 6 Dimensions Capital and Curative Ventures. Previous investors, including Fund +, VIVES II and SRIW, as well as SFPI, also participated in this funding round. For more information, please visit www.iteostherapeutics.com.   For further information, please contact: Michel Detheux, CEO iTeos Therapeutics info@iteostherapeutics.com  Amber Fennell, Mathew Neal, Sukaina Virji, Hendrik Thys Consilium Strategic Communications +44 203 709 5700 iteos@consilium-comms.com Sarah McCabe and Carl Mauch Stern Investor Relations, Inc. + 1 212 362 1200 iTeos@sternir.com   

  • iTeos Therapeutics to Present Data at 2018 SITC Annual Meeting
    Corporate

    iTeos Therapeutics to Present Data at 2018 SITC Annual Meeting

    Gosselies, Belgium – November 6, 2018 – iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announced the presentation of two posters on its novel A2Areceptor antagonist and TIGIT antibody programs, at the upcoming Society for Immunotherapy of Cancer (SITC) 33rdAnnual Meeting, taking place from November 7-11, 2018 in Washington, D.C. “The expanding breadth of knowledge and understanding of the suppressive tumor microenvironment has been  fundamental to the design and development of iTeos’ best-in-class oncology drug candidates,” said Michel Detheux, Ph.D., Chief Executive Officer of iTeos. “The preclinical data presented at SITC demonstrate how our adenosine A2Areceptor antagonist can maintain potency in a high adenosine environment, uniquely evading the limitations faced by repurposed A2Areceptor antagonists. Enabled by the same approach, our TIGIT antagonist monoclonal antibody induces strong anti-tumor efficacy in both monotherapy and in combination with anti-PD1 for more potent activity. We are excited by these findings and look forward to advancing both of these programs into the clinic in the first half of 2019.”  The details of the two presentations are as follows: Title: EOS100850, an insurmountable and non-brain penetrant A2Areceptor antagonist, inhibits adenosine-mediated T cell suppression, demonstrates anti-tumor activity and shows best-in class characteristics. Date & Time:Friday, November 9, 2018; 12:20 – 1:50 p.m. and 7:00 – 8:30 p.m. Authors: Houthuys, et al. Poster Number: 667 Key Takeaways: Adenosine levels are elevated in many tumor microenvironments, promoting tumor immune evasion EOS100850 reverses inhibition of immune cell function by potently inhibiting A2A receptor signalling  In both in vitroand in vivotumor models, EOS100850 induces long standing and specific immune protection   Title: Antitumor efficacy of anti-TIGIT antagonist antibody EOS884448 is mediated by a dual mechanism of action involving restoration of T cell effector functions and preferential depletion of Tregs. Date & Time: Saturday, November 10, 2018; 12:45 – 2:15 p.m. and 6:30 – 8:00 p.m. Authors: Hoofd, et al. Poster Number: 666 Key Takeaways: EOS884448 is a fully human, potent and specific disruptor of the immunosuppressive binding of CD155 to TIGIT in the tumor microenvironment Due to its Fc receptor engagement, EOS884448 not only inhibits CD155 binding but also targets for destruction cells that over-express TIGIT (e.g. Tregs) in the tumor microenvironment EOS884448 exhibits efficacy in in vivotumor models and is more effective when combined with other checkpoint inhibitors About iTeos’ Adenosine A2AReceptor Inhibitor (EOS100850) The adenosine A2Areceptor is the main adenosine receptor expressed on immune cells, which promotes immune suppression, leading to tumor evasion. iTeos’ best-in-class A2Areceptor antagonist, EOS100850, restores T-cell activation inhibited by adenosine. EOS100850 promotes anti-tumor efficacy in mouse tumor models in combination with several immune-checkpoint inhibitors, retains high potency in the presence of elevated intra-tumoral adenosine concentrations, and is non-brain penetrant. EOS100850 is currently being evaluated for safety and efficacy in preclinical models. About iTeos’ Human Anti-TIGIT Antibody (EOS884448) TIGIT is an immunosuppressive receptor expressed on lymphoid cell populations. TIGIT expression increases in cancer patients and marks exhausted T cells. EOS884448 is an antagonist antibody against human TIGIT. Preclinical studies show its potency to restore T cell function and to preferentially deplete Treg cells in cancer patient material. ADCC/ADCP-enabling isotypes of a-TIGIT surrogate Ab show potent monotherapy efficacy in murine tumor models that correlates to increased T cell activation and reduced Treg infiltration of tumors. EOS884448 demonstrates classical human IgG pharmacokinetics profile and a good developability profile. EOS884448 is currently being evaluated for safety and efficacy in preclinical models. About iTeos Therapeutics  iTeos Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing next generation immunotherapies. The Company is advancing EOS100850, an insurmountable and non-brain penetrant adenosine A2A receptor antagonist, into a Phase I trial in the second half of 2018. A second program for its human ADCC-enabling anti-TIGIT antibody (EOS884448) is expected to enter the clinic in 2019. Based in Gosselies, Belgium and Cambridge, MA, iTeos Therapeutics was founded out of the Ludwig Institute for Cancer Research (LICR) and the de Duve Institute (Université Catholique de Louvain) in 2011. In June 2018, the Company completed a $75 million (€64 million) Series B financing led by MPM Capital, alongside new investors HBM Partners, 6 Dimensions Capital and Curative Ventures. All previous investors including Fund +, VIVES II and SRIW, as well as SFPI, also participated in this funding round.For more information, please visit www.iteostherapeutics.com. For further information, please contact: Michel Detheux, CEO iTeos Therapeutics info@iteostherapeutics.com   Amber Fennell, Mathew Neal, Sukaina Virji, Hendrik Thys Consilium Strategic Communications +44 203 709 5700 iteos@consilium-comms.com   Sarah McCabe and Carl Mauch Stern Investor Relations, Inc. + 1 212 362 1200 iTeos@sternir.com

  • iTeos Therapeutics to Participate in Upcoming U.S. Conferences in September
    Corporate

    iTeos Therapeutics to Participate in Upcoming U.S. Conferences in September

    Gosselies, Belgium – August 29, 2018 – iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announced that Michel Detheux, Ph.D., Chief Executive Officer of iTeos, will present in two upcoming U.S. conferences in September.  Citi’s 13th Annual Biotech Conference on Wednesday, September 5, 2018 at 11:15 a.m. ET in Boston, MA. Wells Fargo Securities 2018 Healthcare Conference on Thursday, September 6, 2018 at 3:40 p.m. ET in Boston, MA.   About iTeos Therapeutics  iTeos Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing next generation immunotherapies. The Company is advancing EOS100850, an insurmountable and non-brain penetrant adenosine A2A receptor antagonist, into a Phase I trial in the second half of 2018. A second program for its human ADCC-enabling anti-TIGIT antibody (EOS884448) is expected to enter the clinic in 2019. Based in Gosselies, Belgium and Cambridge, MA, iTeos Therapeutics was founded out of the Ludwig Institute for Cancer Research (LICR) and the de Duve Institute (Université Catholique de Louvain) in 2011. In June 2018, the Company completed a $75 million (€64 million) Series B financing led by MPM Capital, alongside new investors HBM Partners, 6 Dimensions Capital and Curative Ventures. All previous investors including Fund +, VIVES II and SRIW, as well as SFPI, also participated in this funding round.For more information, please visit www.iteostherapeutics.com. For further information, please contact: Michel Detheux, CEO iTeos Therapeutics info@iteostherapeutics.com   Amber Fennell, Mathew Neal, Sukaina Virji, Hendrik Thys Consilium Strategic Communications +44 203 709 5700 iteos@consilium-comms.com   Sarah McCabe and Carl Mauch Stern Investor Relations, Inc. + 1 212 362 1200 iteos@sternir.com

  • iTeos Therapeutics to Participate in Upcoming U.S. Conferences in August
    Corporate

    iTeos Therapeutics to Participate in Upcoming U.S. Conferences in August

    Gosselies, Belgium – August 6, 2018 – iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announced that management will participate in two upcoming U.S. conferences in August.  Managementwill be available for one-on-one meetings at the Oppenheimer Newport Summit for Revolutionary Biotechnology, on Monday, August 13, 2018 in Newport, Rhode Island. Michel Detheux, Ph.D., Chief Executive Officer of iTeos, will present a company overview at the 2018 Wedbush PacGrow Healthcare Conference on Tuesday, August 14, 2018 at 1:20 p.m. ET in New York, NY.     About iTeos Therapeutics  iTeos Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing next generation immunotherapies. The Company is advancing EOS100850, an insurmountable and non-brain penetrant adenosine A2A receptor antagonist, into a Phase I trial in the second half of 2018. A second program for its human ADCC-enabling anti-TIGIT antibody (EOS884448) is expected to enter the clinic in 2019. Based in Gosselies, Belgium and Cambridge, MA, iTeos Therapeutics was founded out of the Ludwig Institute for Cancer Research (LICR) and the de Duve Institute (Université Catholique de Louvain) in 2011. In June 2018, the Company completed a $75 million (€64 million) Series B financing led by MPM Capital, alongside new investors HBM Partners, 6 Dimensions Capital and Curative Ventures. All previous investors including Fund +, VIVES II and SRIW, as well as SFPI, also participated in this funding round.For more information, please visit www.iteostherapeutics.com.   For further information, please contact: Michel Detheux, CEO iTeos Therapeutics info@iteostherapeutics.com   Amber Fennell, Mathew Neal, Sukaina Virji, Hendrik Thys Consilium Strategic Communications +44 203 709 5700 iteos@consilium-comms.com   Sarah McCabe and Carl Mauch Stern Investor Relations, Inc. + 1 212 362 1200 iTeos@sternir.com

  • iTeos Therapeutics Appoints Scott Chappel as Chief Scientific Officer
    Corporate

    iTeos Therapeutics Appoints Scott Chappel as Chief Scientific Officer

    Gosselies, Belgium – July 3, 2018 – iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announced the appointment of Scott Chappel, Ph.D., as its Chief Scientific Officer (CSO). Reporting to Chief Executive Officer Michel Detheux, Ph.D., Dr. Chappel will be responsible for expanding the pipeline and leading the preclinical development of the Company’s best-in-class immuno-oncology programs that target the tumor microenvironment to improve the outcomes for cancer patients.  “We are delighted that Scott has joined iTeos as CSO. He has been a leader in the life sciences sector for more than three decades and is an accomplished scientist who has directed research that has led to the development of several FDA-approved and marketed biological products,” commented Michel Detheux, Ph.D., Chief Executive Officer of iTeos. “His experience will be invaluable to the next phase of our growth as we build an attractive pipeline and transition our programs into the clinic.” With significant biotech experience and a strong scientific research and drug development track record, Dr. Chappel has founded and held several senior leadership roles in companies developing oncology and other novel therapies. Prior to joining iTeos, he was a founder and Chief Technology Officer at Surface Oncology, where he oversaw all antibody generation, engineering, production and characterization as well as all preclinical IND-enabling studies and GMP manufacturing of antibodies. He was also a founder and Chief Scientific Officer at Arteaus Therapeutics (acquired by Eli Lilly in 2014) and Tokai Pharmaceuticals, where he worked to develop an oral therapeutic for the treatment of prostate cancer. Prior to Tokai, he held roles as a Senior Vice President of Research at Dyax and as a Chief Scientist at Serono.  “I am thrilled to join iTeos as CSO and look forward to working with Michel and the team to rapidly advance the Company’s pipeline of high-value, immuno-oncology programs targeting the tumor microenvironment,” added Scott Chappel, Ph.D, Chief Scientific Officer of iTeos. “I am also very excited about the potential therapeutic benefits of EOS100850, an adenosine A2A antagonist, and EOS884448, an anti-TIGIT antibody, which we expect to move into the clinic within 12 months.” About iTeos Therapeutics  iTeos Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing next generation immunotherapies. The Company is advancing EOS100850, an insurmountable and non-brain penetrant adenosine A2A receptor antagonist, into a Phase I trial in the second half of 2018. A second program for its human ADCC-enabling anti-TIGIT antibody (EOS884448) is expected to enter the clinic in 2019. Based in Gosselies, Belgium and Cambridge, MA, iTeos Therapeutics was founded out of the Ludwig Institute for Cancer Research (LICR) and the de Duve Institute (Université Catholique de Louvain) in 2011. In June 2018, the Company completed a $75 million (€64 million) Series B financing led by MPM Capital, alongside new investors HBM Partners, 6 Dimensions Capital and Curative Ventures. All previous investors including Fund +, VIVES II and SRIW, as well as SFPI, also participated in this funding round. For more information, please visit www.iteostherapeutics.com. For further information, please contact: Michel Detheux, CEO iTeos Therapeutics info@iteostherapeutics.com   Amber Fennell, Mathew Neal, Sukaina Virji, Hendrik Thys Consilium Strategic Communications +44 203 709 5700 iteos@consilium-comms.com   Sarah McCabe Stern Investor Relations, Inc. + 1 212 362 1200 sarah@sternir.com  

  • iTeos Therapeutics Expands Board of Directors with the Appointment of David Hallal as Chairman and Tim Van Hauwermeiren as an Independent Director
    Corporate

    iTeos Therapeutics Expands Board of Directors with the Appointment of David Hallal as Chairman and Tim Van Hauwermeiren as an Independent Director

    - Two new appointments follow oversubscribed $75 million (€64 million) Series B financing and support next stage of iTeos’ growth Gosselies, Belgium – June 27, 2018 – iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announced the appointment of David Hallal,  former Chief Executive Officer of Alexion Pharmaceuticals, and Tim Van Hauwermeiren, Chief Executive Officer of argenx, to its board of directors. David has been appointed Chairman and Tim joins as an independent non-executive director.  “David and Tim are both extremely well regarded executives and we are thrilled to have them join the iTeos Board at this stage in our growth. Their combined commercial experience running large biotechnology companies will be invaluable as we advance our innovative next-generation immuno-oncology pipeline and expand our presence in the U.S.,” said Michel Detheux, Ph.D., Chief Executive Officer of iTeos. “Our recent financing and diversified Board put us in an even stronger position to rapidly move our promising therapies into the clinic and to design additional therapeutic candidates based on our industry-leading drug discovery and early clinical development expertise.” David Hallal brings nearly 30 years of senior executive leadership experience in growing and operating several of the world’s most successful biotechnology companies. David spent more than 10 years at Alexion Pharmaceuticals as Chief Executive Officer, Chief Operating Officer and Chief Commercial Officer and played a central role in transforming the company from a development-stage company in 2006 to a commercial-stage company operating in more than 50 countries with three approved products and more than $3 billion in annual revenues by 2016. Prior to Alexion, David held leadership positions at Amgen, Biogen and Eyetech. He also serves as Chairman of Scholar Rock (Nasdaq: SRRK).  Tim Van Hauwermeiren is currently Chief Executive Officer of argenx (Euronext & Nasdaq: ARGX), which he co-founded in 2008 and where he has also served on the Board since July 2014. At argenx, Tim has created a multi-billion-dollar enterprise with three therapies in mid- to late-stage development. Tim has more than 20 years of general management and business development experience across the life sciences and consumer goods sectors. Previously, he held senior leadership roles at Ablynx and Procter & Gamble.  “It’s an exciting time of growth and expansion at iTeos as it prepares to transition its highly differentiated adenosine A2A receptor antagonistinto the clinic, and I am delighted to join the Board as Chairman,” said David Hallal. “Together with Michel, Tim and the other Board members, I will be focused on executing the Company’s strategy to develop innovative therapies that can transform the lives of patients suffering with cancer.” “iTeos is proving to be a key player in the emerging cancer immunotherapy space and I am very much looking forward to working with the team to progress iTeos’ pipeline and provide guidance to help the Company realize its full potential,” added Tim Van Hauwermeiren. iTeos’ Board of Directors now consists of David Hallal (Chairman); Ansbert Gadicke, M.D.; Christiana Bardon M.D. MBA; Priyanka Belawat, Ph.D.; Tim Van Hauwermeiren, MSc, EMBA; Chris Buyse, MBA, Jonathan Skipper, Ph.D. and Michel Detheux, Ph.D. (CEO). About iTeos Therapeutics  iTeos Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing next generation immunotherapies. The Company is advancing EOS100850, an insurmountable and non-brain penetrant adenosine A2A receptor antagonist, into a Phase I trial in the second half of 2018. A second program for its human ADCC-enabling anti-TIGIT antibody (EOS884448) is expected to enter the clinic in 2019. Based in Gosselies, Belgium and Cambridge, MA, iTeos Therapeutics was founded out of the Ludwig Institute for Cancer Research (LICR) and the de Duve Institute (Université Catholique de Louvain) in 2011. In June 2018, the Company completed an oversubscribed $75 million (€64 million) Series B financing led by MPM Capital, alongside new investors HBM Partners, 6 Dimensions Capital and Curative Ventures. All previous investors including Fund +, VIVES II and SRIW, as well as SFPI, also participated in this funding round.For more information, please visit www.iteostherapeutics.com.   For further information, please contact: Michel Detheux, CEO iTeos Therapeutics info@iteostherapeutics.com   Amber Fennell, Mathew Neal, Sukaina Virji, Hendrik Thys Consilium Strategic Communications +44 203 709 5700 iteos@consilium-comms.com   Sarah McCabe Stern Investor Relations, Inc. + 1 212 362 1200 sarah@sternir.com